Evaluate Whether Combination Therapy With Methotrexate and Raptiva in Psoriasis Patients is Safe and Increases Efficacy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
Psoriasis
Interventions
DRUG

Methotrexate

Initial dose 5 mg, then 15 mg per week

DRUG

Raptiva

Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg

Trial Locations (1)

95816

University of California, Davis Medical Center Department of Dermatology, Sacramento

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

University of California, Davis

OTHER

NCT00368654 - Evaluate Whether Combination Therapy With Methotrexate and Raptiva in Psoriasis Patients is Safe and Increases Efficacy | Biotech Hunter | Biotech Hunter